According to Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a subsidiary of the company's innovative pharmaceutical holding subsidiary, has successfully completed the first clinical trial of Nericovir GST-HG141, a class 1 innovative drug for the treatment of hepatitis B, successfully enrolled the first test subjects at Shulan (Hangzhou) Hospital on July 25, 2025. The company will continue to accelerate the progress of clinical research on innovative drugs and strive to provide better scientific solutions for hepatitis B patients as soon as possible.

Zhitongcaijing · 07/25/2025 09:57
According to Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a subsidiary of the company's innovative pharmaceutical holding subsidiary, has successfully completed the first clinical trial of Nericovir GST-HG141, a class 1 innovative drug for the treatment of hepatitis B, successfully enrolled the first test subjects at Shulan (Hangzhou) Hospital on July 25, 2025. The company will continue to accelerate the progress of clinical research on innovative drugs and strive to provide better scientific solutions for hepatitis B patients as soon as possible.